Collegium Pharmaceutical Q4 2023 Adj EPS $1.58 Beats $0.66 Estimate, Sales $149.75M Beat $147.82M Estimate
Portfolio Pulse from Benzinga Newsdesk
Collegium Pharmaceutical reported Q4 2023 adjusted EPS of $1.58, surpassing the $0.66 estimate, with sales of $149.75M exceeding the $147.82M forecast. This represents a 15.53% increase in sales compared to the same period last year.
February 22, 2024 | 9:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Collegium Pharmaceutical's Q4 2023 earnings and sales exceeded analyst expectations, with a significant year-over-year sales growth.
The substantial beat on both earnings per share and sales estimates, coupled with a notable year-over-year sales increase, is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100